Rapid Medical宣布任命James Romero为美洲区总裁

2021-01-14 国际文传 国际文传

经验丰富的神经血管器械高管将领导美国、加拿大和拉丁美洲的商业化工作

以色列约克南和佛罗里达州劳德代尔堡--(美国商业资讯)--专注于开发一流响应式可调节神经血管器械的公司Rapid Medical宣布James Romero出任公司美洲区总裁。Romero先生将负责公司治疗出血性和缺血性卒中患者的先进神经血管技术在美国、加拿大和拉丁美洲的增长和商业拓展。

Romero先生拥有在成长期和大型医疗器械公司长达20年的销售领导经验。在加入Rapid Medical之前,他效力于美敦力(Medtronic),最近的职务是该公司神经血管部门北美销售副总裁。凭借对卒中市场的广泛了解,他带领该公司度过一段大幅增长和转型期,在市场上取得了领先。

Rapid Medical首席执行官、联合创始人Ronen Eckhouse评论道:“James带来了神经血管领域的丰富经验和深厚知识,将极大地促进我们的商业发展。我们计划今年仅在美国就推出三款产品。随着我们在全美洲不断拓展我们的产品阵容,James对该市场及其动态的认识将对我们的成功发挥不可或缺的作用。”

Rapid Medical美洲区新总裁James Romero补充道:“Rapid Medical的器械阵容可增强对手术结果的控制,并有望彻底改变卒中治疗。我对该团队和公司迄今为止的成就印象深刻。Rapid Medical和卒中治疗的未来令人振奋。”

关于Rapid Medical

Rapid Medical正在开发改变神经血管治疗格局的器械。Rapid Medical的器械运用新颖的制造技术,是首批可远程调节的工具,可提供更好的控制以实现更好的手术结果。TIGERTRIEVER™、COMANECI™和COLUMBUS™/DRIVEWIRE均获得CE认证,可在欧洲使用。COMANECI™和DRIVEWIRE™同时获得FDA核准。

原文阅读:http://www.businesswirechina.com/zh/news/45490.html

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1746262, encodeId=ec171e4626252, content=<a href='/topic/show?id=0673e997283' target=_blank style='color:#2F92EE;'>#美洲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79972, encryptionId=0673e997283, topicName=美洲)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c0735680798, createdName=kord1994, createdTime=Sat Apr 03 01:09:49 CST 2021, time=2021-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1859099, encodeId=708e1859099d9, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Mon Dec 13 15:09:49 CST 2021, time=2021-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1533586, encodeId=a002153358646, content=<a href='/topic/show?id=7583114e529' target=_blank style='color:#2F92EE;'>#Medical#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11475, encryptionId=7583114e529, topicName=Medical)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbe912466517, createdName=海豹, createdTime=Sat Jan 16 07:09:49 CST 2021, time=2021-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590813, encodeId=595715908135d, content=<a href='/topic/show?id=0c0b115e4cf' target=_blank style='color:#2F92EE;'>#MES#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11574, encryptionId=0c0b115e4cf, topicName=MES)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=874617863969, createdName=longqijun254, createdTime=Sat Jan 16 07:09:49 CST 2021, time=2021-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610857, encodeId=b852161085e0c, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Jan 16 07:09:49 CST 2021, time=2021-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=916555, encodeId=a1e89165558b, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59321624668, createdName=zb1235672, createdTime=Thu Jan 14 16:22:14 CST 2021, time=2021-01-14, status=1, ipAttribution=)]
    2021-04-03 kord1994
  2. [GetPortalCommentsPageByObjectIdResponse(id=1746262, encodeId=ec171e4626252, content=<a href='/topic/show?id=0673e997283' target=_blank style='color:#2F92EE;'>#美洲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79972, encryptionId=0673e997283, topicName=美洲)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c0735680798, createdName=kord1994, createdTime=Sat Apr 03 01:09:49 CST 2021, time=2021-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1859099, encodeId=708e1859099d9, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Mon Dec 13 15:09:49 CST 2021, time=2021-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1533586, encodeId=a002153358646, content=<a href='/topic/show?id=7583114e529' target=_blank style='color:#2F92EE;'>#Medical#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11475, encryptionId=7583114e529, topicName=Medical)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbe912466517, createdName=海豹, createdTime=Sat Jan 16 07:09:49 CST 2021, time=2021-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590813, encodeId=595715908135d, content=<a href='/topic/show?id=0c0b115e4cf' target=_blank style='color:#2F92EE;'>#MES#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11574, encryptionId=0c0b115e4cf, topicName=MES)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=874617863969, createdName=longqijun254, createdTime=Sat Jan 16 07:09:49 CST 2021, time=2021-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610857, encodeId=b852161085e0c, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Jan 16 07:09:49 CST 2021, time=2021-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=916555, encodeId=a1e89165558b, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59321624668, createdName=zb1235672, createdTime=Thu Jan 14 16:22:14 CST 2021, time=2021-01-14, status=1, ipAttribution=)]
    2021-12-13 jeanqiuqiu
  3. [GetPortalCommentsPageByObjectIdResponse(id=1746262, encodeId=ec171e4626252, content=<a href='/topic/show?id=0673e997283' target=_blank style='color:#2F92EE;'>#美洲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79972, encryptionId=0673e997283, topicName=美洲)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c0735680798, createdName=kord1994, createdTime=Sat Apr 03 01:09:49 CST 2021, time=2021-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1859099, encodeId=708e1859099d9, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Mon Dec 13 15:09:49 CST 2021, time=2021-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1533586, encodeId=a002153358646, content=<a href='/topic/show?id=7583114e529' target=_blank style='color:#2F92EE;'>#Medical#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11475, encryptionId=7583114e529, topicName=Medical)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbe912466517, createdName=海豹, createdTime=Sat Jan 16 07:09:49 CST 2021, time=2021-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590813, encodeId=595715908135d, content=<a href='/topic/show?id=0c0b115e4cf' target=_blank style='color:#2F92EE;'>#MES#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11574, encryptionId=0c0b115e4cf, topicName=MES)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=874617863969, createdName=longqijun254, createdTime=Sat Jan 16 07:09:49 CST 2021, time=2021-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610857, encodeId=b852161085e0c, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Jan 16 07:09:49 CST 2021, time=2021-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=916555, encodeId=a1e89165558b, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59321624668, createdName=zb1235672, createdTime=Thu Jan 14 16:22:14 CST 2021, time=2021-01-14, status=1, ipAttribution=)]
    2021-01-16 海豹
  4. [GetPortalCommentsPageByObjectIdResponse(id=1746262, encodeId=ec171e4626252, content=<a href='/topic/show?id=0673e997283' target=_blank style='color:#2F92EE;'>#美洲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79972, encryptionId=0673e997283, topicName=美洲)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c0735680798, createdName=kord1994, createdTime=Sat Apr 03 01:09:49 CST 2021, time=2021-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1859099, encodeId=708e1859099d9, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Mon Dec 13 15:09:49 CST 2021, time=2021-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1533586, encodeId=a002153358646, content=<a href='/topic/show?id=7583114e529' target=_blank style='color:#2F92EE;'>#Medical#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11475, encryptionId=7583114e529, topicName=Medical)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbe912466517, createdName=海豹, createdTime=Sat Jan 16 07:09:49 CST 2021, time=2021-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590813, encodeId=595715908135d, content=<a href='/topic/show?id=0c0b115e4cf' target=_blank style='color:#2F92EE;'>#MES#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11574, encryptionId=0c0b115e4cf, topicName=MES)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=874617863969, createdName=longqijun254, createdTime=Sat Jan 16 07:09:49 CST 2021, time=2021-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610857, encodeId=b852161085e0c, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Jan 16 07:09:49 CST 2021, time=2021-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=916555, encodeId=a1e89165558b, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59321624668, createdName=zb1235672, createdTime=Thu Jan 14 16:22:14 CST 2021, time=2021-01-14, status=1, ipAttribution=)]
    2021-01-16 longqijun254
  5. [GetPortalCommentsPageByObjectIdResponse(id=1746262, encodeId=ec171e4626252, content=<a href='/topic/show?id=0673e997283' target=_blank style='color:#2F92EE;'>#美洲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79972, encryptionId=0673e997283, topicName=美洲)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c0735680798, createdName=kord1994, createdTime=Sat Apr 03 01:09:49 CST 2021, time=2021-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1859099, encodeId=708e1859099d9, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Mon Dec 13 15:09:49 CST 2021, time=2021-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1533586, encodeId=a002153358646, content=<a href='/topic/show?id=7583114e529' target=_blank style='color:#2F92EE;'>#Medical#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11475, encryptionId=7583114e529, topicName=Medical)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbe912466517, createdName=海豹, createdTime=Sat Jan 16 07:09:49 CST 2021, time=2021-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590813, encodeId=595715908135d, content=<a href='/topic/show?id=0c0b115e4cf' target=_blank style='color:#2F92EE;'>#MES#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11574, encryptionId=0c0b115e4cf, topicName=MES)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=874617863969, createdName=longqijun254, createdTime=Sat Jan 16 07:09:49 CST 2021, time=2021-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610857, encodeId=b852161085e0c, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Jan 16 07:09:49 CST 2021, time=2021-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=916555, encodeId=a1e89165558b, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59321624668, createdName=zb1235672, createdTime=Thu Jan 14 16:22:14 CST 2021, time=2021-01-14, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1746262, encodeId=ec171e4626252, content=<a href='/topic/show?id=0673e997283' target=_blank style='color:#2F92EE;'>#美洲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79972, encryptionId=0673e997283, topicName=美洲)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c0735680798, createdName=kord1994, createdTime=Sat Apr 03 01:09:49 CST 2021, time=2021-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1859099, encodeId=708e1859099d9, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Mon Dec 13 15:09:49 CST 2021, time=2021-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1533586, encodeId=a002153358646, content=<a href='/topic/show?id=7583114e529' target=_blank style='color:#2F92EE;'>#Medical#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11475, encryptionId=7583114e529, topicName=Medical)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbe912466517, createdName=海豹, createdTime=Sat Jan 16 07:09:49 CST 2021, time=2021-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590813, encodeId=595715908135d, content=<a href='/topic/show?id=0c0b115e4cf' target=_blank style='color:#2F92EE;'>#MES#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11574, encryptionId=0c0b115e4cf, topicName=MES)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=874617863969, createdName=longqijun254, createdTime=Sat Jan 16 07:09:49 CST 2021, time=2021-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610857, encodeId=b852161085e0c, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Jan 16 07:09:49 CST 2021, time=2021-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=916555, encodeId=a1e89165558b, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59321624668, createdName=zb1235672, createdTime=Thu Jan 14 16:22:14 CST 2021, time=2021-01-14, status=1, ipAttribution=)]
    2021-01-14 zb1235672

相关资讯

FDA批准新的医疗器械漏洞评分工具CVSS

通用漏洞评分系统(Common Vulnerability Scoring System,CVSS)被用于标定IT系统漏洞的严重程度,但是在某些领域(如工业控制系统或医疗

国家药监局:今日起,将试点启用医疗器械电子注册证!

日前,国家药监局发布关于试点启用医疗器械电子注册证的公告,自2020年10月19日至2021年8月31日,试点启用医疗器械电子注册证,试点发放范围为自公告之日起新批准的国产第三类、进口第二、三类首次注

2019年全国医疗器械主营收入达7200多亿元

中国药品监督管理研究会3日发布《中国医疗器械行业发展报告(2020)》。报告显示,2019年全国医疗器械主营收入达7200多亿元,同比增长12%。

医疗器械如何转型?集采是挑战也是机会,加速国产替代深耕自主创新才是出路

2020年,医疗器械行业逆势成为新风口,除了利好政策频出之外,资本市场也瞄准了行业中创新性突出的企业大力加码。在此背景下,医疗器械企业该如何在行业快速发展阶段,拥抱政策,应对变化?又该如何捕捉多层次发

拓展阅读

国家药监局:严把医疗器械质量安全关

加强医疗器械质量安全风险会商,提升医疗器械质量安全监管的针对性、靶向性和实效性。

九大方面!2021年度中国医疗器械标准管理年报出炉

2021年,国家药监局以推动高质量发展为主题,以规范管理为切入点,严格落实“最严谨的标准”要求,统筹推动医疗器械标准各项工作。

集采之后中国医疗健康趋势与投资逻辑(上)

9月8日-9日,由海通证券举办的第十届海通医药CEO高端论坛在上海陆家嘴举行,本次海通医药高端CEO论坛由海通证券研究所发起,由海通证券研究所、投行部、债券部、并购部、海通开元、海通国际共同主办,聚焦

CMDE医疗器械技术审评专家库第四批外聘专家候选人公示!

根据《医疗器械技术审评中心外聘专家管理办法》有关要求, CMDE按照规定遴选条件及程序,依据科学发展、技术进步以及审评工作需要,开展了第四批外聘专家候选人遴选工作,